SG11201406495UA - Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent - Google Patents
Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agentInfo
- Publication number
- SG11201406495UA SG11201406495UA SG11201406495UA SG11201406495UA SG11201406495UA SG 11201406495U A SG11201406495U A SG 11201406495UA SG 11201406495U A SG11201406495U A SG 11201406495UA SG 11201406495U A SG11201406495U A SG 11201406495UA SG 11201406495U A SG11201406495U A SG 11201406495UA
- Authority
- SG
- Singapore
- Prior art keywords
- halofenate
- gout
- patients
- inflammatory agent
- treating hyperuricemia
- Prior art date
Links
- BJBCSGQLZQGGIQ-UHFFFAOYSA-N 2-acetamidoethyl 2-(4-chlorophenyl)-2-[3-(trifluoromethyl)phenoxy]acetate Chemical compound C=1C=C(Cl)C=CC=1C(C(=O)OCCNC(=O)C)OC1=CC=CC(C(F)(F)F)=C1 BJBCSGQLZQGGIQ-UHFFFAOYSA-N 0.000 title 1
- 201000005569 Gout Diseases 0.000 title 1
- 201000001431 Hyperuricemia Diseases 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 229940121363 anti-inflammatory agent Drugs 0.000 title 1
- 239000002260 anti-inflammatory agent Substances 0.000 title 1
- 229950000958 halofenate Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261624186P | 2012-04-13 | 2012-04-13 | |
| PCT/US2013/036474 WO2013155478A1 (en) | 2012-04-13 | 2013-04-12 | Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201406495UA true SG11201406495UA (en) | 2014-11-27 |
Family
ID=49325641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201406495UA SG11201406495UA (en) | 2012-04-13 | 2013-04-12 | Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20130274331A1 (https=) |
| EP (1) | EP2836209A4 (https=) |
| JP (1) | JP2015512948A (https=) |
| KR (1) | KR20150002799A (https=) |
| CN (1) | CN104602686A (https=) |
| AU (1) | AU2013245675B2 (https=) |
| CA (1) | CA2870014A1 (https=) |
| CL (1) | CL2014002728A1 (https=) |
| EA (1) | EA028495B1 (https=) |
| HK (1) | HK1204913A1 (https=) |
| IL (1) | IL235154A0 (https=) |
| MX (1) | MX2014012376A (https=) |
| PH (1) | PH12014502282A1 (https=) |
| SG (1) | SG11201406495UA (https=) |
| WO (1) | WO2013155478A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6356684B2 (ja) | 2012-11-02 | 2018-07-11 | マレイ・アンド・プール・エンタープライゼズ・リミテッド | コルヒチン誘導体の投与による心血管イベントの処置または予防 |
| CA2909370A1 (en) | 2013-04-16 | 2014-10-23 | Murray And Poole Enterprises Limited | Sustained-release formulations of colchicine and methods of using same |
| US9907751B2 (en) | 2016-03-10 | 2018-03-06 | RxOMEG Therapeutics LLC | Composition and method of use of colchicine oral liquid |
| US10226423B1 (en) * | 2017-12-20 | 2019-03-12 | RxOMEG Therapeutics LLC | Colchicine drug-to-drug interactions |
| JP7850976B2 (ja) * | 2021-08-31 | 2026-04-24 | 国立大学法人広島大学 | 体液サンプリング容器 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7576131B2 (en) * | 1999-06-04 | 2009-08-18 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
| US6262118B1 (en) * | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
| UA109638C2 (uk) * | 2008-03-13 | 2015-09-25 | Сполуки та спосіб зниження рівня сечової кислоти | |
| CN102123595A (zh) * | 2008-03-14 | 2011-07-13 | 因特里赫伯有限责任公司 | 抑制龋齿形成的甘草棒棒糖 |
| US20100137235A1 (en) * | 2008-10-15 | 2010-06-03 | Mutual Pharmaceutical Company, Inc. | Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics |
| ES2698396T3 (es) * | 2011-11-04 | 2019-02-04 | Cymabay Therapeutics Inc | Métodos para tratar los brotes de gota |
| CN109908124A (zh) * | 2011-11-04 | 2019-06-21 | 西玛贝医药公司 | 利用卤芬酯或卤芬酸以及第二尿酸降低剂治疗痛风患者中高尿酸血症的方法 |
| US9060987B2 (en) * | 2011-11-04 | 2015-06-23 | Cymabay Therapeutics, Inc. | Methods for treating gout flares |
| CN104066323A (zh) * | 2011-11-04 | 2014-09-24 | 西玛贝医药公司 | 用于治疗患者亚群中痛风的方法 |
-
2013
- 2013-04-12 WO PCT/US2013/036474 patent/WO2013155478A1/en not_active Ceased
- 2013-04-12 CA CA2870014A patent/CA2870014A1/en not_active Abandoned
- 2013-04-12 CN CN201380030570.9A patent/CN104602686A/zh active Pending
- 2013-04-12 SG SG11201406495UA patent/SG11201406495UA/en unknown
- 2013-04-12 KR KR20147031687A patent/KR20150002799A/ko not_active Withdrawn
- 2013-04-12 MX MX2014012376A patent/MX2014012376A/es unknown
- 2013-04-12 EA EA201491870A patent/EA028495B1/ru not_active IP Right Cessation
- 2013-04-12 EP EP13776027.8A patent/EP2836209A4/en not_active Withdrawn
- 2013-04-12 AU AU2013245675A patent/AU2013245675B2/en not_active Ceased
- 2013-04-12 JP JP2015505961A patent/JP2015512948A/ja active Pending
- 2013-04-12 HK HK15103663.3A patent/HK1204913A1/xx unknown
- 2013-04-12 US US13/862,262 patent/US20130274331A1/en not_active Abandoned
-
2014
- 2014-10-10 PH PH12014502282A patent/PH12014502282A1/en unknown
- 2014-10-10 CL CL2014002728A patent/CL2014002728A1/es unknown
- 2014-10-19 IL IL235154A patent/IL235154A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20130274331A1 (en) | 2013-10-17 |
| CL2014002728A1 (es) | 2015-06-19 |
| EP2836209A4 (en) | 2015-11-25 |
| MX2014012376A (es) | 2015-06-05 |
| PH12014502282A1 (en) | 2014-12-15 |
| WO2013155478A1 (en) | 2013-10-17 |
| AU2013245675B2 (en) | 2017-02-09 |
| EA201491870A1 (ru) | 2015-03-31 |
| KR20150002799A (ko) | 2015-01-07 |
| CN104602686A (zh) | 2015-05-06 |
| IL235154A0 (en) | 2014-12-31 |
| AU2013245675A1 (en) | 2014-10-30 |
| CA2870014A1 (en) | 2013-10-17 |
| EA028495B1 (ru) | 2017-11-30 |
| HK1204913A1 (en) | 2015-12-11 |
| EP2836209A1 (en) | 2015-02-18 |
| JP2015512948A (ja) | 2015-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2627368B8 (de) | Verfahren und vorrichtung zur messung und behebung von systemänderungen in einer vorrichtung zur behandlung von blut | |
| SG11201401189WA (en) | Benzothiazol- 6 -yl acetic acid derivatives and their use for treating an hiv infection | |
| EP2627331A4 (en) | METHODS OF TREATING HYPERURICEMIA AND RELATED DISEASES | |
| GB2504861B8 (en) | Electrophoretic mobility measurement cell and measurement apparatus and method using the same | |
| ZA201300055B (en) | Treatment of gout and hyperuricemia | |
| SG11201401811WA (en) | Method for preventing and/or treating insulin resistance | |
| IL226352A0 (en) | שקיטה@לטיפול@עם@מעקב@braf | |
| EP2865409A4 (en) | NEEDLE-BODY BODY AND MANUFACTURING METHOD FOR NEEDLE-BODY BODY | |
| FI20115893L (fi) | Menetelmä retention säätämiseksi ja menetelmässä käytettävä välituote | |
| PL2815769T3 (pl) | FAM19A5 do zastosowania w diagnostyce i leczeniu uszkodzeń OUN | |
| PT2663864T (pt) | Método de avaliação de imunodiversidade e seu uso | |
| EP2739352A4 (en) | MULTIMODAL ELECTROTHERAPY PROCESS AND DEVICE | |
| EP2761016A4 (en) | REDOX REAGENT COMPOSITION FOR ELECTROCHEMICAL BIOSENSOR AND BIOSENSOR CONTAINING THE SAME | |
| PL2613798T5 (pl) | Zastosowanie lizosomalnej kwaśnej lipazy do leczenia niedoboru lizosomalnej kwaśnej lipazy u pacjentów | |
| EP2593109A4 (en) | METHOD AND FORMULATIONS FOR THE TREATMENT OF SIALIC ACID DEFICIENCIES | |
| SG10201401598RA (en) | Anaerobic treatment method and apparatus | |
| IL236145A0 (en) | System and method for biological treatment of wastewater | |
| EP2867239A4 (en) | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES | |
| IL232384A0 (en) | Use of preparations containing halofanate or halophanic acid to treat gout | |
| EP2922536A4 (en) | USE OF BUCILLAMINE IN THE TREATMENT OF GOUTTE | |
| DK3434276T3 (da) | Fremgangsmåde og farmaceutisk sammensætning til anvendelse i behandlingen af kræft | |
| ZA201403575B (en) | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent | |
| EP2929835A4 (en) | DEVICE FOR MEASURING THE COMPOSITION OF A BODY, METHOD FOR MEASURING THE COMPOSITION OF A BODY AND METHOD FOR CORRECTING THE MEASUREMENT OF THE COMPOSITION OF A BODY | |
| SG11201406495UA (en) | Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent | |
| ZA201304353B (en) | Remedial composition and treatment methods |